Breast cancer

Indexed in Crossref

191 abstracts matching breast cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 09:58 UTC. This is a keyword search, not the complete abstract book.

• E23412
  Longitudinal trends in pembrolizumab uptake for triple-negative breast cancer (TNBC): A comparative analysis of Appalachian and non-Appalachian populations at a tertiary care center.

  Rayli Pichardo, Yazan Abu Omar
• E12680
  Real-world outcomes in triple negative breast cancer (TNBC) in patients with residual disease after neoadjuvant therapy (NEOCAPE).

  Adrian Wong, Alyssa Francis, Jessica Rodrigues, Bader Alshamsan et al.
• E12674
  Impact of neoadjuvant immunotherapy on safety of axillary de-escalation in triple-negative breast cancer (TNBC): A propensity score–matched analysis.

  Zheng Qu, Zheng Li, Hongzhe Zhang, Jennifer Q. Zhang et al.
• E13724
  Racial and ethnic differences in breast-conserving surgery after neoadjuvant chemotherapy for HER2-positive and triple-negative breast cancer.

  Alanna J. Hickey, Fangbai Sun, Fangyong Li, Ellie Proussaloglou et al.
• E13124
  Comparative efficacy and safety of novel agents versus standard chemotherapy in first-line (1L) locally advanced or metastatic triple-negative breast cancer (TNBC): A systematic review and network meta-analyses.

  Aneeta Channar, Arifa Bibi, Sumeeta Bhogal, Ramsha Zardari et al.
• E12548
  Real-world outcomes and cross-resistance of sequential antibody-drug conjugate therapy in HER2-low and triple-negative breast cancer: A systematic review.

  Trishtha Agarwal, Jay Desai, Kaandeeban Mohanraj, Harini Raj Shankar Raj
• 2602
  Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in combination with pembrolizumab in patients with unresectable advanced melanoma or triple-negative breast cancer (TNBC).

  Stephane Dalle, James F. Spicer, Adi Diab, Toby Batten et al.
• E12678
  Treatment patterns and clinical outcomes in patients with triple-negative breast cancer (TNBC) and residual disease (RD) after neoadjuvant chemoimmunotherapy.

  Nadia Bianco, Carmine Valenza, Monica Milano, Riccardo Asnaghi et al.
• 2524
  Phase 1b dose-expansion study of IMC-002, a anti-CD47 monoclonal antibody, in patients with advanced triple negative breast cancer (TNBC).

  Ji Hyung Hong, Keun Seok Lee, Sung Hoon Sim, Kyung Hae Jung et al.
• E12735
  Adjuvant (Ad) and neoadjuvant (NAd) strategies in higher risk hormone receptor–positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC): Moroccan real-world outcomes.

  Hassan Abdelilah Tafenzi, Youssef AIT Takniouine, Farah Choulli, Ismail Essadi et al.
• E12723
  CCND1 amplification and breast cancer–specific survival in estrogen receptor–positive, HER2-negative disease.

  Regan Laird, Mia Wallach
• LBA1003
  Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.

  Jiong Wu, Jian Zhang, Quchang Ouyang, Yiqun Du et al.
• 543
  Real-world effectiveness and safety of adjuvant capecitabine in triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy.

  Anbarasan Sekar, Sanjana Malokar, Sushmita Rath, Prabhat Ghanshyam Bhargava et al.
• E13110
  Aromatase independent estradiol synthesis in triple-negative breast cancer cells.

  Andrew P. Jackson, Jennifer Yannucci, Himangshu Bose
• TPS659
  Pre-operative chemotherapy versus surgery first with peri-operative interventions in early triple-negative and HER2-positive breast cancer: An open-label, phase 3, randomized controlled trial (PRaCTiSE).

  Shalaka Prakash Joshi, Rohini W. Hawaldar, Vaibhav Vanmali, Ashwini Dewade et al.
• 1026
  Development and evaluation of a novel digital pathology image analysis pipeline for prediction of clinical outcomes with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in triple-negative breast cancer (TNBC).

  Sara M. Tolaney, John Kang, Jeong Hwan Kook, Zhongliang Zhou et al.
• E12660
  T-cell receptor (TCR) repertoire dynamics of response to neoadjuvant chemo-immunotherapy in triple- negative breast cancer (TNBC).

  Nickolas Stabellini, Prerana Parthasarathy Bangalore, Iluja Gautam, Pat A. Rayman et al.
• 3034
  Real-world effectiveness of sacituzumab govitecan (SG) versus trastuzumab deruxtecan (T-DXd) in HER2-negative (HER2-) metastatic breast cancer (MBC) in China: A propensity-score–matched study.

  Biyun Wang, Mu Li, Yannan Zhao, Gang Li et al.
• E13127
  Neoadjuvant systemic therapy for triple-negative breast cancer: A safety-net health system’s experience.

  Prisca Mbonu, Rajnandini Aswani, Kalyani Narra
• E12728
  Derivation and external validation of a prognostic nomogram for HER2-negative early breast cancer in young Chinese females: A population-based study.

  Ziqing Kong, Weihong Zhao
• E13130
  A real-world study of triple-negative breast cancer patients with brain metastases: A multicenter retrospective analysis.

  Meiling Wang, Weihong Zhao
• E12624
  De-escalation of axillary surgery in clinically node-negative early-stage HR-positive, HER2-negative breast cancer.

  Petr Krivorotko, Arina Gorina, Alexander Emelyanov, Tengiz Tabagua et al.
• E12583
  AI-based assessment of tumor-infiltrating lymphocytes (TILs) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy versus chemo-immunotherapy.

  Ilana Schlam, Khalid AbdulJabbar, Hillary Heiling, Haixi Yan et al.
• 1125
  Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).

  Shipra Gandhi, Sachin Kumar Deshmukh, Madison T. Canning, Dario Trapani et al.
• 576
  ILCness to stratify lobular-like breast cancer biology and as an outcome independent of CDH1 mutation in early ER-positive/HER2-negative breast cancer.

  Masanori Oshi, Sasagu Kurozumi, Mayu Hizume, Akimitsu Yamada et al.
• E13034
  Efficacy, tolerability, and outcomes of generic palbociclib in metastatic HR-positive, HER2-negative breast cancer: An ambispective study from a tertiary cancer center in South India.

  Anilkumar Thazhatha Jose
• E12650
  Integrative spatial omics to identify determinants of response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

  Chi-Cheng Huang, Chih-Yi Hsu, Ling-Ming Tseng
• E12664
  Determinants of pathologic complete response in early-stage triple-negative breast cancer at a single institution.

  Peter Egwom, Aparna Nanduru, Rishitha Mantri, Seyon Chung et al.
• E12592
  Association of Schwann cells with immune-cold tumor microenvironment in triple-negative breast cancer.

  Kei Kawashima, Masanori Oshi, Akimitsu Yamada, Kazutaka Narui et al.
• E14564
  Characterization of ENTPD1/CD39-mediated myeloid-T-cell crosstalk and its role in immunotherapy response in triple-negative breast cancer.

  Xiaojian Ni, Zi Han Hu
• E12639
  Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy in early-stage triple-negative breast cancer: A systematic review and meta-analysis.

  Ashutosh Modi, Prathyusha Nair
• E13528
  Early deviations from guideline-concordant care in triple-negative breast cancer: A patient-reported analysis.

  Rebekkah Schear, Marcela Mazo- Canola, Laura Housman, Kandis Backus et al.
• E12712
  Refusal of chemotherapy, surgery, and radiation in non-metastatic triple-negative breast cancer.

  Shawn Michael Doss, Rebecca Mai, Alicia H. Arnold, Danny Yakoub et al.
• E12703
  Benefit of chemotherapy on survival in women aged ≥ 70 with HR-positive, HER2-negative breast cancer and N2-like nodal burden: A population-based analysis.

  Noor Khalid, Mohammad Baraa Boozo, Waqas Azhar
• E24073
  Palliative care utilization in metastatic triple-negative breast cancer: A National Cancer Database analysis.

  Cher Ying Foo, Ojasav Sehrawat, Waqar Haque, Akshjot Puri et al.
• E13117
  Triple-negative breast cancer: Real-world evidence from a national oncologic reference center in Panama.

  Ricardo Gollini, Moises Cukier, Rodrigo DeAntonio, Joel Alexander Moreno Rios et al.
• E12710
  Age-related immune toxicity and treatment outcomes in triple-negative breast cancer treated with pembrolizumab.

  Grace Gorecki, Oyepeju Folashade Abioye, Bana Antonios, Colin Eamon Champ et al.
• 1099
  Real-world comparative safety and outcomes of ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: A propensity score–matched sensitivity analysis.

  Noura Abbas, Gary Goldman, Layal Sharrouf
• E12715
  Real-world outcomes of neoadjuvant chemo-immunotherapy in triple-negative breast cancer at a safety-net institution.

  Marian M. Varda, Daniel Park, Julia Lynch, Andrew Hwang et al.
• 1002
  First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

  David W. Cescon, Tiffany A. Traina, Peter Schmid, Javier Cortes et al.
• 3093
  Chemotherapy as a shaper of immune communication in the triple-negative breast cancer microenvironment.

  David Otohinoyi, Sravya Sri Kuchipudi, Archa Rajesh, Precious Idogun et al.
• E13132
  Association of triple-negative breast cancer with decreased T score of femoral neck at the time of osseous metastasis.

  Jean Schneider, Young Jin Suh, young Yi An, Hyun Joo Choi
• 1014
  ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).

  Carlos H. Barrios, Sara A. Hurvitz, Sara M. Tolaney, Javier Cortes et al.
• E12751
  Factors associated with clinical presentation and survival in early-onset triple-negative breast cancer: A real-world analysis.

  Shawn Michael Doss, Rebecca Mai, Alicia H. Arnold, Danny Yakoub et al.
• E12652
  Clinically significant immune-related adverse events with perioperative pembrolizumab in early triple-negative breast cancer: Analysis of trial and real-world evidence.

  Sheikh Abdullah, Rajan Desai, Mariana Marrero Castillo
• E12501
  Spatial transcriptome to identify biomarkers for endocrine sensitivity of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC).

  Yujing Tan, Jiani Wang, Ying Fan, Binghe Xu et al.
• E12559
  Predictive and prognostic value of MRI radiomics in patients with hormone-receptor–positive, HER2-negative breast cancer: A multicenter study.

  Qinmei Xu, Vincent Reid, Bradley Feiger, John A. Cole et al.
• E12633
  Evaluating physician perspectives on neoadjuvant immunotherapy and chemotherapy in early-stage triple-negative breast cancer.

  Alyssa Francis, Sharon McGee, Terry L. Ng, Mark J. Clemons et al.
• E12589
  Predictive value of PET-CT and tumor biology for pathological complete response in triple-negative breast cancer treated with neoadjuvant pembrolizumab: A real-world analysis.

  Niranjan Vijayaraghavan, Sankar Srinivasan, Kritthivasan Venkatakrishnan
• E13000
  Triple-negative oligometastatic breast cancer: A retrospective cohort.

  Jean Louis Lacaze, Bastien Cabarrou, Ciprian Chira, Thibaut Cassou Mounat et al.
• E12507
  Impact and prognosis of pembrolizumab combination in neoadjuvant chemotherapy for triple-negative breast cancer: A single-center retrospective study.

  Tomomi Fujisawa, Takeshi Miyamoto, Shoko Tokuda, Yasuhiro Yanagita et al.
• E13087
  Analysis of eligibility and reporting standards for older patients with hormone receptor–positive, HER2-negative metastatic breast cancer (HR+ MBC) in pivotal phase III clinical trials, 2015-2025.

  Sidharth Mahajan, Lawrence Nguyen, Jennifer Audrey Weiss, Gretchen Genevieve Kimmick
• E12718
  Real-world patterns of dose reduction and early discontinuation of abemaciclib for early-stage, hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer in insured United States adults.

  Carolyn T. Thorpe, Richa Gairola
• E12654
  Landscape of peripheral immune response induced by multimodal thermal therapy combined with chemoimmunotherapy in patients with early-stage HER2-negative breast cancer.

  Fei-Lin Qu, Zelu Zhang, Ke Wang, Yue Lou et al.
• E12659
  Net clinical value of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer: Integrating efficacy heterogeneity and treatment burden.

  Luisana Sisca, Mariam Grazia Polito, Alessio Cortellini, Bruno Vincenzi et al.
• 1119
  The role of FOXM1 in regulating immune memory in triple-negative breast cancer and targeting FOXM1 to develop a therapeutic vaccine.

  Jian Huang, Virginia G. Kaklamani, Manjeet Rao, Nicolas Toshiaki Ryujin
• 1135
  Impact of protein–energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: A real-world analysis.

  Vaishali Deenadayalan, Vasanthan Muthusamy Kumarasamy, Kriti Ahuja, Malak Alharbi et al.
• E13031
  Healthcare system gaps in access to HER2-directed chemotherapy in early-stage HER2-positive breast cancer: A scoping review.

  Nehchal Bedi, Camelia Arsene
• 562
  Predicting recurrence and survival in hormone receptor–positive (HR+)/HER2-negative (HER2–) early breast cancer (EBC) with machine learning models: Optimization of model complexity.

  Frederick Howard, Peter A. Fasching, Yeon Hee Park, Cesar Augusto Santa-Maria et al.
• E12527
  Risk stratification and age-related disparities with abemaciclib responses in early ER-positive/HER2-negative breast cancer.

  Masanori Oshi, Adrienne Groman, Takako Kuroda, Takuho Okamura et al.
• 570
  Evaluation of whole-exome and whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial.

  Andrew Dooley, Rafaela S. Fontenele, Greg Grasse, Joanna Worley et al.
• E13026
  A HER2-targeted NIR-II fluorescent nanoprobe for precision diagnosis and treatment of HER2-positive breast cancer.

  Bing Liu, Shuzhao Chen, Jie Li, Yongqu Zhang
• TPS1161
  Evaluation of the safety and efficacy of TRC003 in metastatic triple-negative breast cancer: A prospective, open-label, multicenter, single-arm exploratory clinical trial.

  Xiaorong Sun, Yekuan Shi, Chuanbin Bian, Suping Li et al.
• 1134
  Immune infiltration features relative to cancer cell clumps as predictors of survival in triple-negative breast cancer.

  Himangi Srivastava, Jung Hun Oh, Leyla Ebrahimpour, James Mathews et al.
• 605
  Treatment patterns and oncologic outcomes in patients with triple-negative (TN) lobular breast cancer.

  Laura Burns Amin, Xiudong Lei, Lavinia P. Middleton, Kelly Hunt et al.
• E23328
  Antibody-drug conjugate adoption in triple-negative breast cancer through community-based quality improvement.

  Reshma L. Mahtani, Ilona Dewald, Samuel Dooyema, Clare Alexander et al.
• 1136
  Leveraging single-cell trajectory analysis and machine learning to build a robust prognostic classifier for triple-negative breast cancer to pinpoint CCDC171 as a master regulator.

  Jialiang Feng, Jiazhi Mi, Shijie Fang, Hui Yang
• E12504
  The efficacy of adjuvant chemoendocrine versus endocrine therapy alone in hormone receptor-positive, HER2-negative early breast cancer: A meta-analysis of reconstructed individual patient data.

  Khadija Mohib, Maaz Ahmad, Hira Shehzad, Arbab Khalid et al.
• 1087
  Oral estrogen receptor (ER) degraders compared to standard endocrine therapy (ET) in ER-positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC): A systematic review and meta-analysis.

  Hadar Goldvaser, Salome Khutsurauli, Michèle Buchinger, Anton Safonov et al.
• E14531
  Liquid biopsy with peripheral blood mononuclear cells: Deciphering systemic immunity to predict PARPi-immunotherapy efficacy in early HER2-negative breast cancer.

  Xiaying Kuang, Nan Shao, Runyi Ye, Yunjian Zhang et al.
• E12520
  Adjuvant immunotherapy following upfront surgery for stage II–III triple-negative breast cancer: A National Cancer Database Study.

  Madison T. Canning, Xiyuan (Angel) Ji, Lan Lei, Michael A. Schwartz et al.
• 1045
  Overall survival by genomic profile in HER2-positive (HER2+) metastatic breast cancer (mBC): A large US clinico-genomic database study.

  Paolo Tarantino, Xiaodan Mai, Jay Soh, Rani Bansal
• E23417
  Clinicopathologic features and survival outcomes of HER2-low versus HER2-negative (IHC 0) breast cancer in real-world practice.

  Maria Paula Uchima-Vera, Manuela Estrada, Maria Alejandra Gomez-Gutierrez, Mateo Barros et al.
• 2555
  Rab11 family interacting proteins as regulators of T cell recognition and infiltration in triple negative breast cancer.

  Paras R. Sahani, Kathleen Conway, Christopher Kywe, Saffet Guleryuz et al.
• E12647
  Anthracycline- and immunotherapy-free neoadjuvant chemotherapy versus KEYNOTE-522 regimen in early-stage triple-negative breast cancer.

  María Sánchez Esperilla, Iván Corriente Gordón, Maria Yeray Rodriguez Garcés, Maria Teresa Garrido Martínez et al.
• 1122
  AI-driven H&E plasma cell to predict pathological complete response in IO-treated triple-negative breast cancer (Yale; NCT02489448).

  Amritpal Singh, Arpit Aggarwal, Germán Corredor, Tilak Pathak et al.
• 1126
  Single cell spatial profiling for identification of organ-specific immune features in the peritumoral microenvironment of triple-negative breast cancer with liver metastases.

  Jin Sun Bitar, Shatakshi Shewale, David Lin, Yeonjoo Choi et al.
• E13122
  Antibody-drug conjugate plus immunotherapy versus chemotherapy-immunotherapy in PD-L1–positive metastatic triple-negative breast cancer: A trial-anchored analysis.

  Sri Pranita Cherukuri, Gowrishankar Palaniswamy, Prithvi Raghavan, Reshman Naga Kumar Jonnadula et al.
• 1127
  Trends in immunotherapy use and survival outcomes by metastatic pattern in metastatic triple-negative breast cancer.

  Michael Schwartz, Xiyuan (Angel) Ji, Jeffrey M. Switchenko, Madison T. Canning et al.
• E12630
  Real-world clinical outcomes of neoadjuvant pembrolizumab among patients with early-stage triple-negative breast cancer (esTNBC) in a US community oncology setting.

  Amin Mohammed Haiderali, Wilbur Pan, Michael A. Danso, Ila Sruti et al.
• E14009
  Intracranial activity of sacituzumab govitecan in HER2-negative breast cancer brain metastases: A systematic review and meta-analysis.

  Gabriela Gazzoni, Natalia Libonati, Isabella Michelon, Erika Bushatsky et al.
• E12605
  Analysis of the results of whole-exome sequencing of paired samples in patients of the Eurasian population with triple-negative breast cancer and their impact on clinical outcomes.

  Daria Bagdasarova, Irina Eremeeva, Maria Revkova, Egor Veselovsky et al.
• E12562
  AI-driven TILs spatial analysis to identify high-density hot spots as a superior prognostic marker in triple-negative breast cancer.

  Takuma Kobayashi, Kanako C. Hatanaka, Nobumoto Tomioka, Teppei Konishi et al.
• 1131
  Progression-free survival as a surrogate endpoint for overall survival in metastatic triple-negative breast cancer: A systematic review and meta-analysis.

  Yashasvi Srivastava, Shankar Biswas, Elangovan Krishnan, Rahul Falodia et al.
• TPS657
  Stereotactic body radiotherapy (SBRT) combined with PD-1 inhibitor and chemotherapy in early-stage treatment-naive triple-negative breast cancer patients: A multicenter phase III clinical study.

  Lei Liu, Xin Wu, Lan Jie, Ting Luo et al.
• 1030
  Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).

  Shivani K. Thaker, Adam Dugan, Unnati Jariwala, Binyam Yilma et al.
• E24015
  Multi-center real-world validation of the HFA-ICOS cardio-oncology risk tool in HER2-positive breast cancer patients receiving anti-HER2 therapy.

  Lama Alfehaid, Ahmed Alanazi, Nada Alsuhebany, Khaled Alamer et al.
• 1059
  Dual HER2 blockade with or without taxane induction in HR+/HER2+ metastatic breast cancer: A comparative analysis of clinical outcomes.

  Mariah Black, Mostafa Eysha, Rafik ElBeblawy, Momo Arai et al.
• E12651
  Efficacy of neoadjuvant TCHP with primary empegfilgrastim (E) prophylaxis in HER2-positive early breast cancer (HER2+ eBC): Final results of the DEFENDOR SPECIAL study.

  Lyudmila Zhukova, Tansylu Ibragimova, Daria Filonenko, Inna Ganshina et al.
• 1120
  Rare histologic subtypes of triple-negative breast cancer: The impact of immunotherapy on outcomes for metastatic disease.

  Jincong Q. Freeman, Maeve Hennessy, Elizabeth Terman, Apoorva Ravichandran et al.
• E12523
  The effect of adjuvant carboplatin-based chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials.

  Sharvani Alajpur, Kosuke Kawai, Kelly Elizabeth McCann, Nicholas Patrick McAndrew et al.
• 593
  Pathologic complete response in rare histologic subtypes of early-stage triple-negative breast cancer in the era of immunotherapy.

  Maeve Hennessy, Jincong Q. Freeman, Elizabeth Terman, Apoorva Ravichandran et al.
• E23345
  Survival, fertility preservation, and pregnancy after treatment in young patients with BRCA-associated triple-negative breast cancer.

  Akemi Kataoka, Meiko Nishimura, Ayumi Kanazawa, Mikiko Kai et al.
• E13131
  Treatment patterns and outcomes after metastatic recurrence following perioperative chemoimmunotherapy in triple-negative breast cancer (mTNBC).

  Riccardo Asnaghi, Carmine Valenza, Nadia Bianco, Monica Milano et al.
• E12649
  Partial breast irradiation followed by neoadjuvant immunochemotherapy in early TNBC.

  Sung Gwe Ahn, Seungho Baek, Soong June Bae, Yoonwon Kook et al.
• E12741
  Simultaneous anthracycline-based chemotherapy and dual HER2 blockade in early-stage HER2-positive breast cancer: A retrospective analysis.

  Miriam Emmelheinz, Daniel Uwe Reimer, Christine Brunner, Annette Reiner et al.
• E13033
  Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: A multi-center retrospective study.

  Yujing Tan, Yinyin Ye, Ying Fan, Binghe Xu et al.
• TPS1153
  ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor–positive (ER+), HER2-negative (HER2−), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.

  Aditya Bardia, Virginia G. Kaklamani, Joyce O'Shaughnessy, Peter Schmid et al.
• 1054
  Neoadjuvant dalpiciclib combined with letrozole and dual HER2 blockade in HR+/HER2+ breast cancer: First-stage results of the HELEN HER2 017 trial.

  Jiujun Zhu, Zhenduo Lu, Junzhao Wu, Xuhui Guo et al.
• 502
  Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.

  Peter Schmid, Charles E. Geyer, Miguel Martin, Sara A. Hurvitz et al.
• E13052
  Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer.

  Shidi Zhao, Jiuda Zhao, Bin Song, Yingxia Tian et al.
• E12636
  A network meta-analysis of efficacy and safety of neoadjuvant anti-HER2 treatments in HER2-positive early breast cancer.

  Jianbin Li, Hanghang Ma, Feng Li, Fan Li et al.
• TPS1144
  A phase 1b/2 study of QLS1304, a novel, highly potent, and selective dual inhibitor of KAT6A/6B, plus endocrine therapy (ET) in patients (pts) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC).

  Jiong Wu, Jian Zhang, Yongli Jin, Hongying Wei et al.
• E13040
  Efficacy of datopotamab deruxtecan after trastuzumab deruxtecan in metastatic hormone receptor–positive HER2-negative breast cancer: A real-world study.

  Yosuke Aoyama, Yukinori Ozaki, Masahiro Kuno, Emi Taniguchi et al.
• 3071
  Multicenter clinical study of [ 18 F]AlF-HER2-BCH PET/CT as a molecular pathology tool for linear quantification of HER2 expression levels in breast cancer.

  Xiaoyi Guo, Xu Liang, Hua Zhu, Guohong Song et al.
• E13043
  Efficacy and safety of AKT inhibitor NTQ1062 combined with fulvestrant in patients with HR-positive/HER2-negative metastatic breast cancer：a proof-of-concept, multicenter, open-label, nonrandomized, phase Ib/II study.

  Yanchun Meng, Jian Zhang, Yongmei Yin, Yueyin Pan et al.
• 1076
  Efficacy and safety of SPH4336 plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer with brain metastases: A multicenter, single-arm, phase II study.

  Kuikui Jiang, Shusen Wang, Qingyuan Zhang, Jing Sun et al.
• E12594
  Examining the tumor microbiology and microenvironment of patients with triple-negative inflammatory breast cancer receiving KEYNOTE-522.

  Azadeh Nasrazadani, Bora Lim, Angela Alexander, Bisrat G. Debeb et al.
• 531
  Chemotherapy (CT) use by Oncotype DX (O-Dx) recurrence score (RS) in hormone receptor–positive, HER2-negative (HR+/HER2-) invasive lobular carcinoma (ILC): A contemporary National Cancer Database (NCDB) analysis.

  Marija Sullivan, Xiudong Lei, Inimfon Jackson, Jason A. Mouabbi et al.
• E12727
  Treatment response and clinical outcomes of patients with triple negative invasive apocrine breast carcinoma.

  Courtnie Brown, Paige Brown, Alexis Ann LeVee, Marla Lipsyc-Sharf et al.
• E12503
  Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.

  James Fradin, Amber Haugen, Yushan Yang, Adam Kidwell et al.
• E13109
  Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.

  Debasish Tripathy, Milana V. Dolezal, Vandana G. Abramson, Namita Chittoria et al.
• 617
  Structural determinants compared with genetic ancestry and self-reported race in triple-negative breast cancer disparities: A multilevel analysis in an admixed population.

  Patrick De Cerqueira, Rafael Canfield Brianese, André Luiz Cicilini, Solange Moraes Sanches et al.
• E12638
  Real-world efficacy and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: A systematic review and meta-analysis.

  Yousef Joseph, Saad Arsalan Wasti, Saima Gill, Alina Jamshed et al.
• 594
  Association of immunotherapy infusion timing with outcomes in early-stage triple-negative breast cancer.

  Xianghui Zou, Yashran Islam, Victoria Lam, Vicky Ma et al.
• E13061
  Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.

  Zainab Sabir, Mirza Muhammad Hadeed Khawar, Sarjana Singh, Asmaa Abu Obaid et al.
• TPS1149
  HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) unresectable locally advanced or metastatic breast cancer.

  Barbara Pistilli, Surui Hou, Julie Marie Collins, Preeti Khetarpal Sudheendra et al.
• TPS1150
  Camizestrant plus ribociclib in hormone receptor–positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial.

  Javier Cortes, Angel Guerrero-Zotano, Maria Gion, Cristina Alba Torres et al.
• 560
  Prognostic value of an MRI-derived recurrence assay in women with hormone receptor–positive, HER2-negative breast cancer: A retrospective, multi-center analysis.

  Matthew P. Goetz, Qinmei Xu, Vincent Reid, Hari Trivedi et al.
• E12590
  Genomic and clinical characterization of estrogen receptor–positive/HER2-negative early breast cancer: Results from the NextGIM study.

  Chiara Molinelli, Barbara Cardinali, Benedetta Conte, Marco Bruzzone et al.
• TPS1143
  A phase II study evaluating treatment discontinuation of dual anti-HER2 therapy in metastatic HER2-positive breast cancer after five years of sustained complete response (FREEDOME-trial).

  Albert Grinshpun, Amir Sonnenblick, Yasmin Leshem, Salome Khutsurauli et al.
• 1016
  Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).

  Komal L. Jhaveri, Hope S. Rugo, Sara M. Tolaney, Miguel Martin et al.
• LBA1006
  Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.

  Nicholas C. Turner, Komal L. Jhaveri, Aditya Bardia, Naoki Niikura et al.
• 529
  Platinum-based chemotherapy in early-stage, high-risk, triple-negative breast cancer: A systematic review and meta-analysis of randomized trials.

  Jesse Lopes da Silva, Mariana Carvalho Gouveia, Anelise Poluboiarinov Cappellaro, Mariana Macambira Noronha et al.
• E13120
  Real-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: A multicenter cohort from Poland, the Czech Republic, and Slovakia.

  Malgorzata Pieniazek, Milos Holanek, Katarzyna Świderska, Bartosz Gasior et al.
• TPS2698
  A phase II study of the DNA plasmid-based vaccine STEMVAC in patients with metastatic triple-negative breast cancer (mTNBC).

  Brie Chun, Natasha Hunter, William R. Gwin, Andrew L. Coveler et al.
• E13119
  Treatment outcomes with pembrolizumab and chemotherapy in metastatic metaplastic triple-negative breast cancer: Data from a central European cohort.

  Justyna Żubrowska, Malgorzata Podskarbi, Aleksandra Konieczna, Magdalena Szymanik-Resko et al.
• 1079
  Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).

  Nicholas C. Turner, Kevin Kalinsky, Katherine E. Hutchinson, Yanling Jin et al.
• E13507
  Designing a triple-negative breast cancer patient journey: A multi-stakeholder initiative to improve clinical pathways and communication in Italy.

  Nicla Maria La Verde, Luisa Brogonzoli, Adele Sgarella, Laura Cortesi et al.
• 616
  De-escalation of neoadjuvant chemotherapy for HER2-positive breast cancer: A systematic review and meta-analysis.

  Maria Clara Périco Perez
• E13058
  Clinical benefit of oral selective estrogen receptor degraders in ESR1 -mutant, HR-positive, HER2-negative advanced breast cancer: A systematic review and meta-analysis.

  Natalia Nunes, Lorrany Larisse Costa Rodrigues, Lara De Holanda Jucá Silveira, Luiz F. Costa De Almeida et al.
• E15046
  Efficacy and safety analysis of T-DXd versus anti-TROP2 ADCs therapy in HER2-low advanced breast cancer.

  Siyuan Zhang, Zefei Jiang
• 1019
  Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.

  Fumikata Hara, Kan Yonemori, Makiko Ono, Takayuki Ueno et al.
• E12529
  Real-world analysis of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer.

  Mariam Haji, Zunairah Shah, Han Yu, Sheheryar Kairas Kabraji
• 1046
  A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the 1L HER2-positive breast cancer cohort.

  Wen Xia, Hai Hu, Xin Wang, Yuping Sun et al.
• 1078
  BL0175, a novel nano-mediated polypeptide conjugate of protein degrader, in patients (pts) with locally advanced/metastatic HR+/HER2− breast cancer (HR+, HER2- LA/mBC): Initial results from a phase 1 study.

  Nanya Wang, Songling Zhang, Meili Sun, Qing Wen et al.
• 1020
  Impact of bevacizumab on the efficacy of antibody–drug conjugates as later-line treatment of basal-like immune-suppressed triple-negative breast cancer.

  Yin Liu, Fan Yang, Wenjia Zuo, Xi-Yu Liu et al.
• TPS644
  ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.

  Payal Deepak Shah, Angela DeMichele, Paul Wileyto, Sara M. Tolaney et al.
• E13108
  Baseline inflammatory indexes and prognosis for progression-free survival in first-line pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer: A Polish multicenter cohort study.

  Malgorzata Pieniazek, Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Iwona Danielewicz et al.
• E12577
  Impact of neutrophil-to-lymphocyte ratio on pathological response in HER2-positive breast cancer patients: A retrospective analysis.

  Namra Naseer, Ayesha Syed, Naqeeb Ullah
• E13047
  Efficacy and toxicity of CDK4/6 inhibitors in early and metastatic HR+/HER2– breast cancer.

  Ravneet Kaur Dhanoa, Sumin Thapa, Pragnan Kancharla, Shweta Kurian
• E13121
  Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in triple-negative breast cancer: A systematic review and meta-analysis.

  Haseeb Tareen, Allah Dad, Muhammad Arham, Haris Bin Tahir et al.
• E13044
  (RW) post-progression outcomes after first-line (1L) treatment with ribociclib + an aromatase inhibitor (AI) vs AI alone in US patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC).

  Lowell L. Hart, Hope S. Rugo, VK Gadi, Priyanka Sharma et al.
• E12530
  Survival outcomes of high and intermediate-risk hormone receptor (HR)-positive human epidermal growth receptor-2 (HER2)-negative early breast cancer patients (EBC) who did and did not receive (neo)adjuvant chemotherapy.

  Winnie Yeo, Lok-Wa Yuen, Ting Ying Ng, Inda Sung Soong et al.
• 1053
  Intracranial efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer with central nervous system involvement: A systematic review and proportional meta-analysis.

  Dua Azim, Sohail Kumar, Mesum Abbas, Muhammad Moin Ud Din Arshad et al.
• E12673
  Survival outcomes of neoadjuvant versus adjuvant chemotherapy in stage II-III hormone receptor-positive/HER2-negative breast cancer: A propensity score–matched analysis.

  Armando Orlandi, Francesca Salvatori, Lucia Sacco, Giorgia Arcuri et al.
• E15070
  Development of an [18F]-labeled glutamine PET radiotracer to detect serine synthesis pathway activity in HER2-positive breast cancer.

  Darshi N. Shah, Veer Shah, Jules A. Cohen
• 595
  Neoadjuvant chemotherapy combined with toripalimab for triple-negative breast cancer: A prospective, single-arm, multi-center study (NEOTORCH-BREAST02).

  Zhijun Dai, Guansheng Zhong, Ying Chen, Minya Yao et al.
• 600
  Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: Updated efficacy and safety results from the phase II NeoTAPPL study.

  Guozhi Zhang, Wenting Yan, Long Yuan, Jing Liu et al.
• E13111
  Prognostic value of baseline 18F-FDG PET/CT in first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer.

  Marcin Kubeczko, Miroslawa Puskulluoglu, Milos Holanek, Dana Dvorakova et al.
• E13112
  Radiotherapy in symptomatic metastatic triple-negative breast cancer treated with first-line pembrolizumab and chemotherapy: A multinational real-world study.

  Marcin Kubeczko, Miroslawa Puskulluoglu, Milos Holanek, Malgorzata Meluch et al.
• 1084
  Impact of oral SERDs, including giredestrant, on survival in HR+ HER2− metastatic breast cancer: A meta-analysis.

  Changtai Tian, Alison Stopeck, Harry Fruchtman, Anna Andrzejczyk
• 1058
  HER2-targeted tyrosine kinase inhibitors in breast cancer: Real-world analysis of gastrointestinal and musculoskeletal toxicities using the FAERS database.

  Sneha Singh, Shivani Modi, Dawood Findakly
• E13003
  Clinical outcomes of heart failure in breast cancer patients receiving HER2-directed therapy: A retrospective analysis (2016–2020).

  Rabia Iqbal, Ahmad Taimoor Bajwa, Amina Jafar, Madhulika Urella
• 1055
  Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)–permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial.

  Nancy U. Lin, Sarah Heeson, Mahesh Shivhare, Ziqiang (Zack) Cheng et al.
• LBA514
  Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.

  Ciara Catherine O'Sullivan, Kevin Kalinsky, Christina Yau, Anne M. Wallace et al.
• TPS1145
  TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC).

  Diana Bello Roufai, Alexia Savignoni, Frederique Berger, Aurelie Moreira et al.
• E13059
  Tumor immune microenvironment of metastatic HR+ HER2- breast cancer treated with CDK4/6 inhibitors.

  Brie Chun, Cameron Watson, Allison Creason, Andy Kaempf et al.
• E12518
  Patient preferences for duration of adjuvant trastuzumab for HER2+ breast cancer.

  Helena Margaret Earl, Liam J. Schmitt, Monica Peek, Mark J. Ratain et al.
• E13039
  Real-world effectiveness of CDK4/6 inhibitor re-treatment in HR+/HER2- metastatic breast cancer.

  Xi Liang, David D. Stenehjem, Xiangyang Ye, Eleni Maria Gamvroulas et al.
• 1086
  An early resistance genomic state (ERGS) as an identifier of primary CDK4/6 inhibitor failure in HR+/HER2− metastatic breast cancer.

  Mobina Shrestha, Salina Dahal, Vishal Mandal
• E24206
  Interstitial lung disease risk and outcomes across HER2-targeted therapies commonly used in breast cancer: Analysis of real-world FAERS data.

  Sneha Singh, Anubhuti Sharma, Sangam Sangam, Dawood Findakly
• E13020
  Sequential use of antibody-drug conjugates in advanced breast cancer: A real-world study based on HER2 status.

  Gang Li, Qing Qu, W Zhu, Hongwei Zhang et al.
• E13118
  Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia.

  Miroslawa Puskulluoglu, Joanna Kiszka, Aleksandra Konieczna, Milos Holanek et al.
• E13024
  Pyrotinib versus pertuzumab plus trastuzumab and taxane as first-line therapy for HER2-positive advanced breast cancer: A retrospective cohort study using propensity score overlap weighting.

  Xinyue Hang, Jin Yang
• 1009
  Efficacy and safety of camrelizumab combined with docetaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer: The HELEN-Trio 011 randomized clinical trial.

  Zhenzhen Liu, Dechuang Jiao, Xianfu Sun, Jianghua Qiao et al.
• 1124
  Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.

  Aleksandra Konieczna, Malgorzata Meluch, Milos Holanek, Zuzana Bielčiková et al.
• E12760
  Patterns of failure and outcomes in triple-negative compared to estrogen receptor–positive breast cancer.

  Tanun Jitwatcharakomol, Yevgeniya Gokun, Jacob Eckstein, Therese Andraos et al.
• 2588
  Multi-omics analysis from the IMMUcan consortium to identify predictors of chemo-immunotherapy response in early-stage triple-negative breast cancer.

  Andrea Joaquin Garcia, Marcela Carausu, Mattia Rediti, Marie Morfouace et al.
• TPS1163
  A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.

  Kazuki Nozawa, Yukinori Ozaki, Tomohiro Oshino, Kaori Terata et al.
• TPS643
  Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy.

  Hatem Hussein Soliman, Aixa Elena Soyano Muller, Ricardo L. Costa, Hyo S. Han et al.
• 536
  A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer.

  Keith L. Knutson, David W. Hillman, Davitte Cogen, Alvaro Moreno-Aspitia et al.
• 607
  Health-related quality of life with low-dose pembrolizumab plus chemotherapy in early triple-negative breast cancer: Findings from the PLANeT trial.

  Adhip Arora, Hemavathi Baskarane, Ghazal Tansir, Sameer Bakhshi et al.
• E12635
  Pre-operative intratumoral toll-like receptor 9 (TLR9) agonist vidutolimod (Vidu) and stereotactic body radiation therapy (SBRT) in early triple-negative breast cancer (eTNBC): Randomized phase 2 CyberImmunoBreast trial.

  Khalil Zaman, Stephanie Tissot, Estelle Dubruc, Ourania Dafni et al.
• 1544
  Time to treatment initiation for triple-negative breast cancer in Brazil: A call for public health action.

  Fernanda Madasi Pinheiro, Renata Colombo Bonadio, Wesley Antônio Lopes de Lima, Andre Joao Rossi et al.
• 611
  DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients.

  Xiaofei Huo, Tanya W. Moseley, Beatriz Adrada, Clinton Yam et al.
• E13125
  Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.

  Malgorzata Podskarbi, Aleksandra Konieczna, Milos Holanek, Katarzyna Świderska et al.
• E16035
  Liposomal irinotecan plus sintilimab and lenvatinib for second-line advanced HER2-negative gastric/gastro-esophageal junction adenocarcinoma: A phase II trial.

  Yangwei Fan, Xuyuan Dong, Meichen Wang, Yu Shi et al.
• 598
  Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study.

  Zhi-Ming Shao, Ruoxi Wang, Ruijun Zhao, Yang Yu et al.
• 1077
  [ 18 F] Fluoroestradiol PET/CT to guide second-line treatment decision-making in patients with estrogen receptor–positive, HER2-negative advanced breast cancer after progression on first-line aromatase inhibitor and CDK4/6 inhibitor: Primary results of ESTROTIMP.

  Francois Clement Bidard, Romain-David Seban, Stephanie M. van de Ven, Sylvain Ladoire et al.
• 625
  Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.

  Kay T. Yeung, Claudine Isaacs, Marissa Howard-Mcnatt, Christina Yau et al.
• E12609
  Clinical and molecular features of patients with PIK3CA -mutant ( PIK3CA m) ER+/HER2− breast cancer with detectable circulating tumor DNA (ctDNA) in early breast cancer (eBC).

  Niharika Duggirala, Sandro Satta, Bhakti Dwivedi, Philip Miller et al.
• 1073
  (RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US.

  VK Gadi, Lowell L. Hart, Paolo Tarantino, Priyanka Sharma et al.
• E23402
  Recurrence patterns and survival in hormone receptor-positive/HER2-negative early breast cancer: A retrospective analysis from a public oncologic institution in Peru.

  Guillermo Valencia, Alexandra Saavedra, Zaida Morante, Patricia Rioja et al.
• LBA1018
  Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.

  Yen-Shen Lu, Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai et al.
• 1067
  Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.

  Rachel M. Layman, Katarzyna Joanna Jerzak, John Frederick Hilton, Pablo Tolosa Ortega et al.
• 1052
  Molecular imaging as a tool to predict patient outcomes in advanced HER2-low breast cancer on trastuzumab deruxtecan (T-DXd): The FHERAD trial.

  Xiaoyi xiaoyi Guo, Xu Liang, Hua Zhu
• TPS1146
  HER2-positive central nervous system (CNS) surveillance: A study of the feasibility of randomizing women and men with HER2-positive metastatic breast cancer to CNS surveillance versus no surveillance.

  Talvinder Bhogal, Sara Jayne Meade, Ciara O'Brien, Annabel Borley et al.
• TPS1165
  Phase IIa, open-label, multi-center study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399).

  Mark Robson, Timothy A. Yap, Gaorav P. Gupta, Raquel Andrés et al.
• E12668
  Comparative efficacy and safety of anti-HER2 neoadjuvant therapy in early-stage HER2-positive breast cancer: A real-world multicenter analysis.

  Yuqin Zhou, Juncheng Xuhong, Ya Wei, Maoshan Chen et al.
• 1123
  JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study.

  Herui Yao, Zhangzhou Huang, Hong Zong, Min Yan et al.